Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
July 15 2021 - 8:00AM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage
biotechnology company pioneering a precision medicine approach for
the discovery, development, and commercialization of novel
therapeutic and companion diagnostic products for the treatment of
immune-mediated diseases, starting first with inflammatory bowel
disease (IBD), today announced it will host its virtual R&D Day
for analysts and investors at 9:00 a.m. ET on Wednesday, July 28,
2021. The program will showcase development of Prometheus’ lead
candidate, PRA023, focusing on the Phase 2 trial design in
Ulcerative Colitis and Crohn’s Disease.
In addition to presentations by Prometheus’ senior management
team, the R&D Day will feature talks and panel discussions from
renowned key opinion leaders including:
- Tachi Yamada, MD, KBE: Venture
Partner at Frazier Healthcare Partners, former President of the
Bill & Melinda Gates Foundation and former head of R&D at
Takeda & GSK, Chairman of the Board at Prometheus
Biosciences
- Fred Hassan: Director at Warburg
Pincus, LLC, former CEO of Schering-Plough and former director at
Amgen
- Brian Feagan, MD:
gastroenterologist, epidemiologist and Senior Scientific Director
at Alimentiv
- Dermot McGovern, MD, PhD: Director
of Translational Medicine at the Inflammatory Bowel and
Immunobiology Research Institute at Cedars-Sinai
- Umer Raffat: Senior Managing
Director at Evercore ISI
- William Sandborn, MD: Professor of
Medicine at the University of California San Diego, Chairman of
Prometheus Biosciences Scientific Advisory Board
- Stephan Targan, MD: Director of
Inflammatory Bowel and Immunobiology Research Institute at
Cedars-Sinai
The agenda for the Prometheus R&D Day is as follows:
Introduction from the CEO
- Welcome and Perspectives: Mark
McKenna, President & CEO of Prometheus Biosciences
The Science of TL1A in IBD
- TL1A Discovery: Stephan Targan,
MD
- Mechanism of Action for PRA023:
Olivier Laurent, PhD, CTO of Prometheus Biosciences
- Genetic Associations of TL1A: Dermot
McGovern, MD, PhD
- Companion Diagnostic for PRA023:
Laurens Kruidenier, PhD, CSO of Prometheus Biosciences
PRA023 in IBD
- Unmet Need and Implication of
Precision Approach in IBD: William Sandborn, MD
- IBD Study Designs in Ulcerative
Colitis and Crohn’s Disease: Brian Feagan, MD
- PRA023 Phase 2 Trial in Ulcerative
Colitis and Phase 2a in Crohn’s Disease: Allison Luo, MD, CMO of
Prometheus Biosciences
Closing Remarks and Panel Discussion
- Prometheus’ Upcoming Milestones and
Vision for Future Growth: Mark McKenna, President & CEO of
Prometheus Biosciences
- Panel Discussion: Umer Raffat as
Moderator, Senior Managing Director at Evercore
- Tachi Yamada, MD, KBE
- Fred Hassan
- William Sandborn, MD
|
- Allison Luo, MD
- Brian Feagan, MD
- Dermot McGovern, MD, PhD
|
Registration for the event as well as a live and archived
webcast of the R&D Day will be available in the Events section
of the Prometheus Biosciences website.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology
company pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment and diagnosis of
immune-mediated diseases, starting first with IBD. The Company’s
precision medicine platform, Prometheus360TM, combines proprietary
bioinformatics discovery methods with one of the world’s largest
gastrointestinal bioinformatics databases to identify novel
therapeutic targets and develop therapeutic candidates to engage
those targets. Prometheus is headquartered in San Diego, CA.
Forward Looking Statements
Prometheus cautions readers that statements contained in this
press release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
company’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to statements regarding:
the timing of commencement of Prometheus’ Phase 2 clinical trial in
Ulcerative Colitis and its Phase 2a clinical trial in Crohn’s
Disease; Prometheus’ Enroll360 program and the company’s ability to
accelerate enrollment in its planned and other future clinical
trials; and the timing of Prometheus obtaining the final study
results from its Phase 1a clinical trial of PRA023. The inclusion
of forward-looking statements should not be regarded as a
representation by Prometheus that any of our plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in our
business, including, without limitation: Prometheus’ approach to
the discovery and development of precision medicines based on
Prometheus360 is unproven; potential delays in the commencement,
enrollment and completion of clinical trials and preclinical
studies; Prometheus’ dependence on third parties in connection with
product manufacturing, research and preclinical and clinical
testing; Prometheus’ ability to develop companion diagnostics for
our therapeutic product candidates; unexpected adverse side effects
or inadequate efficacy of our product candidates that may limit
their development, regulatory approval and/or commercialization, or
may result in recalls or product liability claims; the results of
preclinical studies and early clinical trials are not necessarily
predictive of future results; Prometheus may not realize any
benefits from our current and any future collaborations; regulatory
developments in the United States and foreign countries;
Prometheus’ ability to obtain and maintain intellectual property
protection for our product candidates and maintain our rights under
intellectual property licenses; Prometheus’ ability to maintain
undisrupted business operations due to the COVID-19 pandemic,
including delaying or otherwise disrupting its clinical trials,
manufacturing and supply chain; and other risks described in
the company’s prior press releases and filings with
the Securities and Exchange Commission (SEC), including
under the heading “Risk Factors” in Prometheus’ most recent
quarterly report on Form 10-Q and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and Prometheus undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Investors:Noel KurdiVP Investor Relations and
Communications(646) 241-4400nkurdi@prometheusbiosciences.com
Media:Juniper PointAmy Conrad(858)
914-1962media@prometheusbiosciences.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024